Amgen Urges Full Fed. Circ. Hearing On Repatha Patents

Law360, Washington (December 7, 2017, 5:08 PM EST) -- Drugmaker Amgen asked the Federal Circuit on Wednesday for an en banc rehearing of a decision that revived a challenge to its patents for Repatha, an antibody-based cholesterol treatment, saying a panel abandoned precedent by rejecting a previously used test for patentability of such drugs and finding admissible evidence that post-dates the challenged patents.

In striking down a lower court’s ruling upholding patents for Repatha, a three-judge panel invalidated the “newly characterized antigen test,” which has been cited in multiple Federal Circuit and U.S. Patent and...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Amgen Inc. v. Sanofi


Case Number

17-1480

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Question)

Date Filed

January 12, 2017

Law Firms

Companies

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.